Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may predict artery health and heart attack risk

NCT ID NCT07589374

Knowledge-focused Sponsor: Hospital de Base Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how metabolic health (measured by a simple blood test) relates to artery stiffness and daily blood pressure changes in 800 adults. Researchers will use routine tests and non-invasive measurements to find better ways to identify people at higher risk for heart disease. No treatments are given—only data collection from standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adults aged 18 to 65 years referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation at a specialized cardiovascular center. Participants will include both normotensive individuals and untreated hypertensive individuals, classified based on 24-hour ABPM measurements. The study will include both previously collected data and prospectively recruited participants evaluated using standardized protocols.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years; * Both sexes; * Referred for ambulatory blood pressure monitoring (ABPM) as part of routine clinical evaluation; * Not receiving antihypertensive medication at the time of assessment; * Availability of valid 24-hour ABPM data; * Availability of carotid-femoral pulse wave velocity (cf-PWV) measurement; * Availability of fasting laboratory data, including glucose and triglycerides, for calculation of the triglyceride-glucose (TyG) index; * Ability and willingness to provide written informed consent (for prospectively recruited participants). Exclusion Criteria: * Use of antihypertensive medication at the time of evaluation; * Cardiac arrhythmias that may interfere with accurate blood pressure or pulse wave velocity measurements; * Invalid or poor-quality ambulatory blood pressure monitoring (ABPM) recordings; * Inability to obtain reliable carotid-femoral pulse wave velocity (cf-PWV) measurements; * Presence of severe vascular disease or conditions affecting arterial waveform assessment; * Missing essential clinical, laboratory, or hemodynamic data required for the primary analysis; * Pregnancy; * Refusal or inability to provide informed consent (for prospectively recruited participants).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial stiffness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome hypertensive disorder Insulin Resistance metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial stiffness Blood pressure variability Cardiovascular risk Hypertension Insulin resistance syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medicine School of São José do Rio Preto

    São José do Rio Preto, São Paulo, 15090-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.